Sana Biotechnology (SANA) News and press releases

Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

30 May 23

Long Ideas, News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy.

Skyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On Tuesday

30 May 23

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

U.S. stocks traded mixed, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.

Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session

15 May 23

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.

Sarepta Therapeutics, C3.ai, monday.com, And Other Big Stocks Moving Higher On Monday

15 May 23

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

U.S. stocks traded lower, with the Dow Jones dropping around 100 points on Monday. Here are some big stocks recording gains in today’s session.

Sana Biotechnology Q1 EPS $(0.43) Beats $(0.49) Estimate

8 May 23

Earnings, News

Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.49) by 12.24 percent. This is a 8.51 percent increase over losses of $(0.47) per share from

Sana Biotechnology Announces Preclinical Data Published In Nature Biotechnology Demonstrating Its Hypoimmune-Engineered Cells Escape Immune Detection And Survive While Remaining Fully Functional

8 May 23

Biotech, News, General

Hypoimmune-modified allogeneic iPSCs evade immune response and rejection without immunosuppression in non-human primate model Long-term survival and immune evasion of hypoimmune-modified allogeneic iPSCs at least

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2023

2 May 23

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

HC Wainwright & Co. Initiates Coverage On Sana Biotechnology with Neutral Rating

2 May 23

News, Initiation, Analyst Ratings

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Sana Biotechnology (NASDAQ:SANA) with a Neutral rating.

Why Sana Biotechnology Shares Are Trading Higher Today

13 Apr 23

Penny Stocks, Small Cap, Movers

Sana Biotechnology (NASDAQ: SANA) shares are trading higher after the company announced the publication of a paper in Nature Communications on hypoimmune-modified allogeneic CD19-directed CAR T cells.

Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

13 Apr 23

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday.

Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday

13 Apr 23

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.

Sana Biotechnology Highlights Publication Of Paper Titled 'Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice' In Science Translational Medicine

12 Apr 23

Biotech, General

Hypoimmune human islet cells normalized glucose in diabetic humanized immunocompetent mouse model and avoided allogeneic and autoimmune rejection by the immune system Similar hypoimmune primary human islet cells

Sana Biotechnology Q4 EPS $(0.40) Beats $(0.51) Estimate

16 Mar 23

Earnings, News

Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.51) by 21.57 percent. This is a 38.46 percent increase over losses of $(0.65) per share

Cellarity Appoints Dr. Gregory J. Moore to Board of Directors

6 Jun 23

Penny Stocks, Small Cap, Press Releases

Cellarity, a life sciences company founded by Flagship

Sana Biotechnology to Present at June 2023 Investor Conferences

31 May 23

News, Press Releases

SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations

Montai Health Adds Industry Leaders to its Board of Directors

17 May 23

Penny Stocks, Small Cap, Press Releases

- Michael Severino, M.D. and Andreas Fibig bring decades of drug development and commercialization leadership experience to Montai

Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry

16 May 23

Press Releases

The company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefit With $50 million in committed capital from Flagship,

Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional

8 May 23

Health Care, Press Releases

Hypoimmune-modified allogeneic iPSCs evade immune response and rejection without immunosuppression in non-human primate model Long-term survival and immune evasion of hypoimmune-modified allogeneic iPSCs at least

Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

2 May 23

News, Press Releases

SEATTLE, May 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that six abstracts highlighting

Sana Biotechnology to Host Research & Development Day

24 Apr 23

News, Press Releases

SEATTLE, April 24, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that management will host a Research

Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model

12 Apr 23

Press Releases

Hypoimmune human islet cells normalized glucose in diabetic humanized immunocompetent mouse model and avoided allogeneic and autoimmune rejection by the immune system Similar hypoimmune primary human islet cells to be

Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization

10 Apr 23

News, Management, Press Releases

Dr. Douglas E. Williams as Head of Research and Development Dr. Gary Meininger as Chief Medical Officer SEATTLE, April 10, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on

Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

16 Mar 23

Earnings, Press Releases

Announced SC291 IND clearance with goal to report initial clinical data this year Expect to initiate investigator-sponsored trial with hypoimmune-modified primary islet cells with potential clinical data this year

Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting

14 Mar 23

News, Health Care, Press Releases

SEATTLE, March 14, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on creating and delivering engineered cells as medicines, today announced that four abstracts, including a